Alzheimer's disease in the Republic of Sakha (Yakutia): realities and expectations
https://doi.org/10.25789/YMJ.2023.84.21
Abstract
Introduction. Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by cognitive decline, primarily loss of memory for recent events. Despite the widespread prevalence of AD in the world, in Russia there is a high level of deficiency in diagnosing the disease. The Republic of Sakha (Yakutia) is a large subject of the Russian Federation; at the beginning of 2023, the population of the Republic was 997,565 people, and over the past 20 years, the share of elderly people (60 years and older) has increased 1.86 times (from 8.3% to 15 ,5%). The aim of the research: to assess the level of diagnosis of Alzheimer's disease and predict the likely number of patients in the Republic of Sakha (Yakutia). Materials and methods: to estimate the number of patients with AD, reports from neurologists of the Republic of Sakha (Yakutia) and official data on the disease provided by the Yakut Republican Medical Information and Analytical Center were analyzed (YRMIAC). To predict the number of patients in the city of Yakutsk and the regions of the Republic of Sakha (Yakutia) for each age group of the population, the maximum and minimum proportions of people who could potentially suffer from AD were calculated. Based on various epidemiological studies, three forecast scripts have been identified: “Chinese”, “Japanese” and “American”. Results and discussion. According to official data, 45 patients diagnosed with AD are registered in the Republic of Sakha (Yakutia), of which 36 (80%) people live in Yakutsk. According to reports from neurologists for 2022, only 7 people are registered at the dispensary with a diagnosis of Alzheimer’s disease. If we extrapolate world data for the Republic Sakha (Yakutia), then the minimum number of patients with Alzheimer's disease should be 4,166.4 people and observed under the “Chinese” script, and the maximum number of patients – 8,428.5 people – under the “American” script. The largest number of patients is predicted in the industrial districts of the republic (Neryungri, Mirny and Aldan). The smallest number of patients with Alzheimer's disease is predicted in the Arctic and Northern districts, especially in Eveno-Bytantaysky and Anabarsky. Conclusion. Alzheimer's disease is one of the leading medical and social problems of the modern world. At this stage in the Republic of Sakha (Yakutia), improved diagnosis of the disease is required for the timely initiation of symptomatic therapy. The predicted number of patients determined by us in the city of Yakutsk and the districts of the Republic can serve as a guideline when screening patients for cognitive impairment.
About the Authors
A. A. TappakhovRussian Federation
Tappakhov Alexey Alekseevich – PhD, Associate Professor; Senior Researcher of the Center for Neurodegenerative Diseases
T. Ya. Nikolaeva
Russian Federation
Nikolaeva Tatyana Yakovlevna – MD, Head of the
Department
A. M. Struchkov
Russian Federation
Struchkov Artur Magnusovich – student
T. E. Popova
Russian Federation
Popova Tatyana Egorovna – MD, Deputy Director
References
1. Vasenina E.E., Levin O.S. Features of the clinical picture and treatment of moderate and severe Alzheimer's disease //S.S. Korsako Journal of Neurology and Psychiatry. – 2015. – Vol. 115 (Special Issue 6). – P. 17-25. DOI:10.17116/jnevro20151156217-25
2. Pre-demental stage of Alzheimer's disease: modern approaches to diagnosis and pharmacotherapy // Doctor.ru. – 2017. – Vol. 8(137). – P. 44-49.
3. The glymphatic system of the brain and its role in the pathogenesis of Alzheimer's disease. Lobzin V.Yu., Kolmakova K.A., Emelin A.Yu., [et al] // Bulletin of the Russian Military Medical Academy. – 2019. – Vol. 1(65). – P. 230-236
4. Koberskaya N.N. Alzheimer's disease // Neurology, neuropsychiatry, psychosomatics. 2019. Vol. 11. P. 52-60. DOI:10.14412/2074-2711-2019-3S-52-60.
5. Koberskaya N.N., Tabeeva G.R. Modern concept of cognitive reserve // Neurology, neuropsychiatry, psychosomatics. 2019. Vol. 11(1). P. 96-102. DOI:10.14412/2074-2711-2019-1-96-102
6. Parfenov V.A. Early diagnosis and treatment of Alzheimer's disease // Medical Council. 2015. Vol. 5. P. 28-33.
7. Federal State Statistics Service for the Republic of Sakha (Yakutia). 8. 2023 Alzheimer’s disease facts and figures // Alzheimer’s Dement. – 2023. – Vol. 19(4). P. 1598-1695. DOI:10.1002/alz.13016
8. Abeysinghe A., Deshapriya R., Udawatte C. Alzheimer’s disease; a review of the pathophysiological basis and therapeutic interventions. Life Sci. 2020; 256:117996. DOI:10.1016/j.lfs.2020.117996
9. Eratne D., Loi S.M., Farrand S., [et al.] Alzheimer’s disease: clinical update on epidemiology, pathophysiology and diagnosis. Australas Psychiatry. 2018; 26(4): 347-357. DOI:10.1177/1039856218762308
10. Hanseeuw B.J., Betensky R.A., Jacobs H.I.L., [et al.] Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study. // JAMA Neurol. 2019; 76(8): 915-924. DOI:10.1001/jamaneurol.2019.1424
11. Andrews S.J., Fulton-Howard B., O’Reilly P. [et al.] Causal Associations Between Modifiable Risk Factors and the Alzheimer’s Phenome. Ann Neurol. 2021; 89(1): 54-65. DOI:10.1002/ana.25918
12. Chan K.Y., Wu J.J., Liu L., [et al.] Epidemiology of Alzheimer’s disease and other forms of dementia in China, 1990-2010: A systematic review and analysis. Lancet. 2013; 381(9882): 2016-2023. DOI:10.1016/S0140-6736(13)60221-4
13. Hendriks S, Peetoom K, Bakker C, [et al.] Global Prevalence of Young-Onset Dementia: A Systematic Review and Meta-analysis. JAMA Neurol. 2021; 78(9): 1080-1090. DOI:10.1001/jamaneurol.2021.2161
14. Mehta K.M., Yeo G.W. Systematic review of dementia prevalence and incidence in United States race/ethnic populations. Alzheimers Dement. 2017; 13(1): 72-83. DOI:10.1016/j.jalz.2016.06.2360
15. Ganguli M, Snitz BE, Saxton JA, et al. Outcomes of Mild Cognitive Impairment by Definition. Arch Neurol. 2011; 68(6): 761-767. DOI:10.1001/archneurol.2011.101
16. Rajan K.B., Weuve J., Barnes L.L., [et al.] Population estimate of people with clinical Alzheimer’s disease and mild cognitive impairment in the United States (2020–2060). Alzheimer’s Dement. 2021; 17(12): 1966-1975. DOI:10.1002/alz.12362
17. Petersen R.C., Lopez O., Armstrong M.J., [et al.]. Practice guideline update summary: Mild cognitive impairment report of the guideline development, dissemination, and implementation. Neurology. 2018; 90(3): 126-135. DOI:10.1212/WNL.0000000000004826
18. Ward A., Crean S., Mercaldi C.J., [et al.]. Prevalence of Apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with alzheimer’s disease: A systematic review and meta-analysis. Neuroepidemiology. 2012; 38(1): 1-17. DOI:10.1159/000334607
19. Ward A., Tardiff S., Dye C., [et al.]. Rate of conversion from prodromal Alzheimer’s disease to Alzheimer’s dementia: a systematic review of the literature. // Dement Geriatr Cogn Dis Extra. 2013; 3(1): 320-332. DOI:10.1159/000354370
20. Xie L., Kang H., Xu Q., et al. Sleep drives metabolite clearance from the adult brain. Science. 2013; 342(6156): 373-377. DOI:10.1126/science.1241224
21. LaPlume A.A., McKetton L., Levine B., [et al.]. The adverse effect of modifiable dementia risk factors on cognition amplifies across the adult lifespan. Alzheimer’s Dement Diagnosis, Assess Dis Monit. 2022; 14(1): 1-8. DOI:10.1002/dad2.12337
22. Zheng Y., Wu Q., Su F., [et al.]. The protective effect of Cantonese. Mandarin bilingualism on the onset of Alzheimer disease. Dement Geriatr Cogn Disord. 2018; 45(3-4): 210-219. DOI:10.1159/000488485
23. Ohara T., Hata J., Yoshida D., [et al.]. Trends in dementia prevalence, incidence, and survival rate in a Japanese community. Neurology. 2017; 88(20): 1925-1932. DOI:10.1212/WNL.0000000000003932
24.
Review
For citations:
Tappakhov A.A., Nikolaeva T.Ya., Struchkov A.M., Popova T.E. Alzheimer's disease in the Republic of Sakha (Yakutia): realities and expectations. Yakut Medical Journal. 2023;(4):88-91. https://doi.org/10.25789/YMJ.2023.84.21